LeeSW,KimHC,LeeHS,,2016,SuhI.Thirty-Year Trends in Mortality from Cerebrovascular Diseases in Korea,,46,507,14
TsayYC,ChenCH,PanWH,,2016,Ages at Onset of 5 CardiometabolicDiseases Adjusting for Nonsusceptibility: Implications for the Pathogenesis of Metabolic Syndrome,Am J Epidemiol,184,366,77
Czupryniak L, Saryusz-Wolska M, Pawlowski M, Wojcik J, Loba J.
Distribution of the components of the NCEP ATP III-defined
metabolicsyndrome in newly diagnosed diabetes and nondiabetes
caucasian subjects; implications for metabolicsyndrome
prevention and
VanuzzoD,PilottoL,MiroloR,,2008,Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation,G Ital Cardiol (Rome),9,6S,17S
StoneNJ,RobinsonJG,LichtensteinAH,BaireyMerzCN,BlumCB,EckelRH,,2014,American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,J Am Coll Cardiol,63,2889,934
AdhyaruBB,JacobsonTA,,2015,New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia,Cardiol Clin,33,181,96
Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P,
Bachorik PS, et al. Non-high-densitylipoproteincholesterollevel as
a predictor of cardiovascular diseasemortality. Arch Intern Med.
2001; 161: 1413-9.
Al-HashmiK,Al-ZakwaniI,Al MahmeedW,ArafahM,Al-HinaiAT,ShehabA,,2016,Non-high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf,J Clin Lipidol,10,368,77
BarkasF,ElisafM,LiberopoulosE,LiontosA,RizosEC,,,,High,13,,
deVriesM,KlopB,Castro Cabezas M.,,2014,The use of the nonfastinglipidprofile for lipid-lowering therapy in clinical practice - point of view,Atherosclerosis,234,473,5
World Health,,1995,Organization (WHO),Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee,854,,
MatthewsDR,HoskerJP,RudenskiAS,NaylorBA,TreacherDF,TurnerRC,,,Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man,Diabetologia1985,28,412,9
NationalCholesterol Education Program (NCEP) Expert,,2002,Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,",Circulation,106,3143,3421
AlbertiKG,ZimmetP,ShawJ,,2005,The metabolic syndrome--a new worldwide definition,Lancet,366,1059,62
Non-HDLCholesterol,,2016,Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events,Arterioscler Thromb Vasc Biol,36,2220,2228
StrufaldiMW,SouzaFI,PucciniRF,,2016,Family history of cardiovascular disease and non-HDLcholesterol in prepubescent non-obese children,Rev Assoc Med,62,347,52
MoriyamaK,TakahashiE,,2016,Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDL Cholesterol in Japanese Subjects with TG Levels ?400 mg/dL,,23,1126,37
AthyrosVG,KatsikiN,KaragiannisA,MikhailidisDP,,2014,The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps,Curr Med Res Opin,30,1701,5
KrumholzHM.,,2014,The new cholesterol and blood pressure guidelines: perspective on the path forward,JAMA,311,1403,5
deNijsT,SnidermanA,de Graaf,,2013,ApoB versus non-HDLcholesterol: diagnosis and cardiovascularrisk management,Crit Rev Clin Lab Sci,50,163,71
CurrOpin Lipidol,,2015,,,26,502,10
SnidermanA,McQueenM,ContoisJ,WilliamsK,FurbergCD,,2010,Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol,,4,152,5
SnidermanAD,LamarcheB,ContoisJH,,2014,Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB,Curr Opin Lipidol,25,461,7
Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF.
Pharmacological Targeting of the AtherogenicDyslipidemia
Complex: The Next Frontier in CVD Prevention Beyond Lowering
LDL Cholesterol. Diabetes. 2016; 65: 1767-78.